Skip to content

Missouri Judge Gives Final Approval to Bayer’s $7.25 Billion Roundup Cancer Settlement

A St. Louis judge on Friday, Nov. 20, 2026, granted final approval to a class settlement under which Bayer’s Monsanto unit will pay as much as $7.25 billion to resolve claims that its Roundup weedkiller causes non-Hodgkin lymphoma. The order from St. Louis Circuit Judge Timothy Boyer clears the way for one of the largest mass-tort resolutions in recent years to begin paying claimants.

The deal, first announced in February, is designed to reach both people who already have a lymphoma diagnosis and those who may be diagnosed in the years ahead. Bayer has long maintained that glyphosate, Roundup’s active ingredient, is safe and has not admitted wrongdoing.

How the Payments Will Work

Rather than a single lump sum, the settlement is structured as a long-running claims program. Monsanto will make declining annual payments into a fund for up to 21 years. Average individual awards are expected to fall between roughly $10,000 and $165,000, with the amount depending on how a person used the product, their age when diagnosed and how severe their illness is.

The agreement also sets aside a separate $1 billion security fund to guard against shortfalls, along with more than $400 million for added compensation in “special circumstances” cases. According to Bayer, the class covers people exposed to Roundup before Feb. 17, 2026, who either have a diagnosis now or receive one within 16 years after final approval.

Objections Did Not Derail the Deal

Some class members had urged the court to reject the settlement, arguing the payouts were too small for people facing a serious cancer. Judge Boyer concluded the average awards were fair, reasonable and adequate, and the objections did not block approval. The window for opt-outs and objections closed on June 4, and the court held a final approval hearing in September.

Bayer has faced roughly 65,000 claims linking the weedkiller to cancer, and more than 30,000 Roundup cases have been filed in Missouri courts alone.

The Supreme Court Backdrop

The settlement was negotiated against a shifting legal landscape. While approval was pending, the U.S. Supreme Court ruled in the Durnell case that federal law preempts state failure-to-warn claims, a theory that sat at the center of much of the Roundup litigation. That decision narrowed the path for plaintiffs pursuing individual suits and reportedly led some people who had planned to opt out to rejoin the class.

Class counsel described the order as delivering guaranteed compensation to people who have waited more than a decade, and said average class awards are more than double those paid through the separate federal multidistrict litigation program. Bayer called the approval a decisive step toward containing its Roundup exposure, a legal burden it inherited when it acquired Monsanto in 2018.

What Comes Next

With final approval in place, attention turns to administering claims and to any appeals from objectors. For Bayer, the order and the Durnell ruling together represent its strongest effort yet to put years of costly Roundup litigation behind it.

Sources